# A Study to Investigate the Effects of Zibotentan/Dapagliflozin Combination Compared to Dapagliflozin Alone in Adult Participants With Chronic Kidney Disease and High Proteinuria

> **NCT06942910** · PHASE2 · RECRUITING · sponsor: **AstraZeneca** · enrollment: 224 (estimated)

## Conditions studied

- Chronic Kidney Disease With High Proteinuria

## Interventions

- **DRUG:** Zibotentan/Dapagliflozin
- **DRUG:** Dapagliflozin

## Key facts

- **NCT ID:** NCT06942910
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-05-07
- **Primary completion:** 2026-07-31
- **Final completion:** 2026-07-31
- **Target enrollment:** 224 (ESTIMATED)
- **Last updated:** 2026-04-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06942910

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06942910, "A Study to Investigate the Effects of Zibotentan/Dapagliflozin Combination Compared to Dapagliflozin Alone in Adult Participants With Chronic Kidney Disease and High Proteinuria". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT06942910. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*